Cargando…
Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer
Interleukin‐6 (IL‐6)/signal transducer and activator of transcription 3 (STAT3) pathway inhibition may overcome chemoresistance of metastatic pancreatic cancer (MPC). We sought to determine the safety and recommended dose of tocilizumab (TCZ), an IL‐6 receptor monoclonal antibody, and biological cor...
Autores principales: | Mitsunaga, Shuichi, Ikeda, Masafumi, Imaoka, Hiroshi, Sasaki, Mitsuhito, Watanabe, Kazuo, Sato, Akihiro, Aoki, Kazunori, Ochiai, Atsushi, Makikawa, Mayu, Nishidate, Masanobu, Yamaguchi, Kyoko, Terao, Kimio, Sawada, Noriaki, Fujitomo, Takashi, Fujii, Etsuko, Kato, Atsuhiko, Tsunoda, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551603/ https://www.ncbi.nlm.nih.gov/pubmed/37605479 http://dx.doi.org/10.1111/cas.15929 |
Ejemplares similares
-
Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021) -
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
por: Kim, Seong-Ryong, et al.
Publicado: (2021) -
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022) -
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022) -
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)